Aurobindo Pharma has reported results for the quarter ended June 30, 2011.
The Company has reported a net loss of Rs 101.58 crore for the quarter ended June 30, 2011 as compared to net profit of Rs 63.34 crore for the quarter ended June 30, 2010. The company’s total income registered growth of 18.77% at Rs 1031.87 crore for the June quarter of FY12 from Rs 868.81 crore for the June quarter of the previous Fiscal.
On Consolidated basis, the Group has reported a net loss of Rs 122.80 crore for the Q1FY12 as compared to net profit of Rs 51.50 crore for the quarter ended June 30, 2010. Its total income has increased by 16.69% at Rs 1079.79 crore for the quarter under review from Rs 925.36 crore for the quarter ended June 30, 2010.
Aurobindo Pharma headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: